MONTREAL, QUEBEC--(MARKET WIRE)--Sep 4, 2007 -- Theratechnologies (Toronto:TH.TO - News) announced it has notified its principal investigators to end recruitment by September 11, 2007 for its confirmatory Phase 3 clinical trial using tesamorelin (TH9507) for the treatment of HIV-associated lipodystrophy. Patients recruited on or before this date will be screened and those eligible will be officially enrolled in the study within the next few weeks.
